---
layout: default
title: Soybean Oil
parent: 僅模型預測 (L5)
nav_order: 924
evidence_level: L5
indication_count: 10
---

# Soybean Oil
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Soybean Oil (DB09422): From Undetermined Original Use to Amenorrhea

## One-Sentence Summary

> No approved original indication is on record for soybean oil (DB09422) in this evidence pack; available literature associates it primarily with intravenous lipid emulsions used in parenteral nutrition.
> The TxGNN model's top prediction is **Amenorrhea (disease)**,
> but this is supported by **0 clinical trials** and **0 publications** — the score reflects model output only, with no corroborating clinical or mechanistic evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no Singapore licenses or original_indications on record; literature describes soybean oil as a component of IV lipid emulsions (parenteral nutrition) |
| Predicted New Indication | Amenorrhea (disease) |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for soybean oil is not available, and no approved original indication is recorded in this evidence pack. The literature collected under this candidate (attached to a different predicted indication, esophageal disease) describes soybean oil almost exclusively as a component of intravenous lipid emulsions used in parenteral nutrition, particularly in surgical or critically ill patients. This role is nutritional/immunomodulatory in nature and does not provide any identifiable mechanistic pathway to amenorrhea.

The evidence pack's own rationale for this prediction states it plainly: there is no clinical trial or literature support for a soybean oil–amenorrhea link, and the high TxGNN score most likely reflects indirect embedding relationships in the knowledge graph around nutrition/lipid-metabolism nodes rather than genuine biological plausibility. The same pattern repeats across most of the top-10 predictions for this drug (bone Paget disease, juvenile Paget disease, dentinogenesis imperfecta, several rare carcinomas) — all rated L5, all annotated by the source pipeline as likely knowledge-graph artifacts rather than credible repurposing hypotheses.

The one partial exception is rank 4, esophageal disease, which does have some clinical trial and literature evidence — but that evidence largely shows dietary/IV fat *inducing or influencing* esophageal symptoms (e.g., acid sensitivity, reflux, perioperative immune modulation) rather than treating disease, and includes a withdrawn trial with zero enrollment. Even the drug's best-evidenced candidate is mechanistically inconsistent and far from actionable. Given this, the amenorrhea prediction at rank 1 should be treated as unsupported model noise rather than a plausible repurposing signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Singapore Market Information

Soybean oil (DB09422) currently has no marketing authorization on record in Singapore (0 registrations; market status: not marketed).

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (amenorrhea) has zero supporting clinical trials or literature, no known mechanism of action, and the drug is not currently marketed in Singapore — this is a pure model prediction (L5) with no clinical or mechanistic corroboration.

**To proceed, the following is needed:**
- Mechanism of action data for soybean oil (DrugBank query, per DG002)
- Regulatory label warnings/contraindications (TFDA or equivalent PDF label parsing, per DG001 — currently blocking)
- Independent literature or preclinical search specifically targeting a soybean oil–amenorrhea (or lipid/endocrine axis) mechanistic hypothesis, since none currently exists in this evidence pack
- If pursuing any candidate from this drug's prediction set, esophageal disease (rank 4) warrants closer review first, as it is the only one with any clinical/literature signal — though that signal is currently inconsistent (symptom-inducing rather than therapeutic) and would need substantial further evidence before advancing past Hold
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

